Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective

Table 4 Results of the base-case analysis

Time horizon		Edaravone dexborneol	Dl-3-n-butylphthalide	Difference
Day 90	Cost (CNY)	19302.20	19979.61	-677.41
	QALY	0.1708	0.1694	0.0014
	ICER			Dominant
5 years	Cost (CNY)	24957.11	25704.09	-746.98
	QALY	2.7230	2.6780	0.0450
	ICER			Dominant
Life-time (40 years)	Cost (CNY)	29185.23	29940.28	-755.05
	QALY	8.0351	7.8736	0.1615
	ICER			Dominant

CNY Chinese Yuan, QALY Quality-adjusted life years, ICER Incremental cost-effectiveness ratio

ISSN: 1471-2458